Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Oncology Research|March 16, 2010
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's diseaseHolbrook Kohrt, Alexandre Johannsen, Richard Hoppe, et al.Blood|September 30, 2010
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumorsMatthew J Goldstein, Bindu Varghese, Joshua D Brody, et al.Journal of Translational Medicine|June 25, 2014
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlationsMutsa T Madondo, Sandra Tuyaerts, Brit B Turnbull, et al.Oncoimmunology|May 8, 2015
Trial watch: Tumor-targeting monoclonal antibodies for oncological indicationsErika Vacchelli, Jonathan Pol, Norma Bloy, et al.Radiation Research|July 4, 2014
Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusionAlexander Filatenkov, Jeanette Baker, Antonia M Müller, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2015
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete RemissionsAlexander Filatenkov, Jeanette Baker, Antonia M S Mueller, et al.The Journal of Clinical Investigation|June 4, 2013
Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsAurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, et al.The American Journal of Pathology|August 21, 2012
CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implicationsMatthew W Anderson, Shuchun Zhao, Aharon G Freud, et al.The Journal of Investigative Dermatology|February 2, 2016
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient PrognosisNicolas Jacquelot, María Paula Roberti, David P Enot, et al.Immunity|May 21, 2015
Interleukin-2 activity can be fine tuned with engineered receptor signaling clampsSuman Mitra, Aaron M Ring, Shoba Amarnath, et al.Pageof 4